Pharma Equity Group A/S

PEG

DK0061155009

Investment Holding Companies

Market Closed - Nasdaq Copenhagen Other stock markets 10:08:32 2024-05-01 am EDT			5-day change	1st Jan Change
0.24 ^DKK	-2.04%		-8.40%	-44.19%

Apr. 10	Pharma Equity Group A/S announced that it has received DKK 7.6 million in funding	CI
Apr. 05	Pharma Equity Group?s subsidiary, Reponex Pharmaceuticals A/S, reports highly positive final results from the phase-2 clinical trial of the company?s patented drug candidate RNX-051	CI

Pharma Equity Group A/S Approves Board Appointments

November 02, 2023 at 10:15 am EDT

Pharma Equity Group A/S at its extraordinary general meeting held on November 2, 2023, approved the election of the Board of Directors: (i) Omar S. Qandeel, and (ii) Martin Engell-Rossen. The Board of Director immediately thereafter constituted itself with Christian Vinding Thomsen as the Chairman of the Board of Directors and Martin Engell-Rossen as the Vice Chairman of the Board of Directors. The Board of Directors will thereafter consist of Christian Vinding Thomsen (Chairman), Martin Engell-Rossen (Vice Chairman), Omar S. Qandeel, Lars Gundorph and Peter Vilmann.

Latest news about Pharma Equity Group A/S

Pharma Equity Group A/S announced that it has received DKK 7.6 million in funding	Apr. 09	CI
Pharma Equity Group?s subsidiary, Reponex Pharmaceuticals A/S, reports highly positive final results from the phase-2 clinical trial of the company?s patented drug candidate RNX-051	Apr. 05	CI
Pharma Equity Group A/S Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 20	CI
Pharma Equity Group A/S Provides Group Earnings Guidance for the Full Year 2024	Mar. 20	CI
Pharma Equity Group A/S announced that it expects to receive DKK 7.1 million in funding	Feb. 06	CI
Pharma Equity Group A/S announced that it has received DKK 8.914795 million in funding	Jan. 24	CI
Pharma Equity Group's Subsidiary (Reponex Pharmaceuticals A/S) Receives Notification from the European Patent Office	Jan. 22	CI
Pharma Equity Group A/S announced that it expects to receive DKK 8.914795 million in funding	Jan. 21	CI
Pharma Equity Group A/S Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Jan. 17	CI
Pharma Equity Group Unit Meets Primary Endpoints in Colon Cancer Treatment Trial	Nov. 16	MT
Pharma Equity Group A/S Announces Positive Preliminary Results from the Phase-2 Clinical Trial	Nov. 16	CI
Pharma Equity Group A/S Approves Board Appointments	Nov. 02	CI
Pharma Equity Group?S Subsidiary Company Reponex Pharmaceuticals A/S Receives Grant of Us Patent for A Method of Treatment on Its Topical Wound-Healing Composition	23-10-31	CI
Pharma Equity Group A/S Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-16	CI
Reponex Pharmaceuticals Set for US Patent for Chronic Wound Treatment Method	23-08-15	MT
Pharma Equity Group A/S Announces Board Changes	23-06-15	CI
Reponex Pharmaceuticals A/S Announces CEO Changes	23-06-14	CI
Reponex Pharmaceuticals A/S Names Dr Christopher M Burton MD, PhD as Chief Medical Officer	23-06-14	CI
Pharma Equity Group A/S Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-10	CI
Pharma Equity Group A/S Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-10	CI
Pharma Equity Group A/S Reports Earnings Results for the Full Year Ended December 31, 2022	23-03-31	CI
Reponex Pharmaceuticals A/S completed the acquisition of Pharma Equity Group A/S.	23-03-23	CI
Blue Vision A/S will Change its Name to Pharma Equity Group A/S	23-02-14	CI
Blue Vision A/S Reports Earnings Results for the Half Year Ended June 30, 2022	22-08-31	CI
Blue Vision A/S (CPSE:BLVIS A) made an offer to acquire Reponex Pharmaceuticals A/S.	22-04-04	CI

Chart Pharma Equity Group A/S

Duration

Period

More charts

Company Profile

Pharma Equity Group A/S, formerly Blue Vision A/S, is a Denmark-based company. The Company's purpose is, without geographical limitation, to be a holding company for companies with life science activities and to be the biopharmaceutical company that develops the local treatments for serious, acute and chronic inflammatory diseases. The Company's purpose is also to invest in shares admitted to trading on a regulated market place or multilateral trading facility and unlisted capital shares as determined by the board of directors in order to achieve long-term value growth while observing appropriate risk diversification as well as other related businesses.

Sector

Investment Holding Companies

Calendar

2024-05-15 - Q1 2024 Earnings Release

More about the company

Income Statement Evolution

More financial data

Sector Other Holding Companies

	1st Jan change	Capi.
PHARMA EQUITY GROUP A/S	-44.19%	35.93M
INVESTOR AB	+16.98%	75.78B
KOÇ HOLDING	+59.45%	17.7B
INVESTMENT AB LATOUR	+2.74%	15.69B
AB INDUSTRIVÄRDEN	+8.60%	14.04B
L E LUNDBERGFÖRETAGEN AB	-0.04%	12.37B
HAL TRUST	+8.96%	11.98B
BAJAJ HOLDINGS & INVESTMENT LIMITED	+5.82%	10.82B
MERITZ FINANCIAL GROUP INC.	+34.35%	10.08B
GROUPE BRUXELLES LAMBERT SA	-1.92%	9.69B